ALLOVIR INC (ALVR)

Company Profile

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The company is headquartered in Waltham, Massachusetts and currently employs 112 full-time employees. The company went IPO on 2020-07-30. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Company Info

ALLOVIR INC

1100 Winter Street

Waltham MASSACHUSETTS 02142

P: 16174332605

CEO: David Hallal

Employees: 112

Website: https://www.allovir.com